ACE-031
Also known as: ACVR2B-Fc · Activin receptor type IIB decoy · Myostatin inhibitor fusion protein
A fusion protein combining the ligand-binding domain of the activin type IIB receptor (ACVR2B) with the Fc region of human IgG1. Acts as a decoy receptor for multiple TGF-beta superfamily members including myostatin, activin A, GDF-11, and BMP9, simultaneously blocking all of them to produce dramatic increases in muscle mass.
What is ACE-031? A fusion protein combining the ligand-binding domain of the activin type IIB receptor (ACVR2B) with the Fc region of human IgG1. Acts as a decoy receptor for multiple TGF-beta superfamily members including myostatin, activin A, GDF-11, and BMP9, simultaneously blocking all of them to produce dramatic increases in muscle mass.
How does ACE-031 work? ACE-031 presents a decoy ACVR2B domain that captures myostatin, activin A, GDF-11, GDF-8, and other TGF-beta family ligands before they can bind to their native receptors. This removes multiple simultaneous brakes on muscle growth. In a Phase 2 trial for Duchenne muscular dystrophy, a single dose increased total lean mass by an average of 2.5 kg within 4 weeks.
Benefits of ACE-031: Simultaneous inhibition of multiple muscle-growth inhibitors (myostatin, activin A, GDF-11); Dramatic lean mass increases — 2.5 kg in 4 weeks in Phase 2 DMD trial; Superior to single myostatin inhibitors or follistatin alone; Potential for muscle wasting diseases (DMD, ALS, cachexia); Anti-aging muscle preservation
ACE-031 dosage: Phase 2 DMD: 1-3mg/kg single SC dose produced 2.5 kg lean mass increase in 4 weeks. Development halted due to vascular side effects (epistaxis, telangiectasias). Research use only with caution.
Research status: Research Only
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/ace-031
Mechanism of Action
ACE-031 presents a decoy ACVR2B domain that captures myostatin, activin A, GDF-11, GDF-8, and other TGF-beta family ligands before they can bind to their native receptors. This removes multiple simultaneous brakes on muscle growth. In a Phase 2 trial for Duchenne muscular dystrophy, a single dose increased total lean mass by an average of 2.5 kg within 4 weeks.
Benefits
- Simultaneous inhibition of multiple muscle-growth inhibitors (myostatin, activin A, GDF-11)
- Dramatic lean mass increases — 2.5 kg in 4 weeks in Phase 2 DMD trial
- Superior to single myostatin inhibitors or follistatin alone
- Potential for muscle wasting diseases (DMD, ALS, cachexia)
- Anti-aging muscle preservation
Side Effects & Risks
- Epistaxis (nosebleeds) — most common side effect in trials
- Gum bleeding
- Telangiectasias (dilated capillaries)
- Development halted in Phase 2 due to vascular side effects
- Serious research compound — vascular safety concerns
Where to Buy ACE-031
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$99.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Research Protocol
- Dose Range
- 1–3 mg/kg/kg
- Frequency
- Single dose or monthly research protocol
- Cycle
- Monthly cycles or as directed
- Routes
- subcutaneous injection
- Notes
- Phase 2 DMD: 1-3mg/kg single SC dose produced 2.5 kg lean mass increase in 4 weeks. Development halted due to vascular side effects (epistaxis, telangiectasias). Research use only with caution.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
Chemical Properties
- CAS Number
- 948557-43-5
- Mol. Weight
- ~55,000 Da (fusion protein)
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About ACE-031
What is ACE-031?▾
A fusion protein combining the ligand-binding domain of the activin type IIB receptor (ACVR2B) with the Fc region of human IgG1. Acts as a decoy receptor for multiple TGF-beta superfamily members including myostatin, activin A, GDF-11, and BMP9, simultaneously blocking all of them to produce dramatic increases in muscle mass.
What are the benefits of ACE-031?▾
Simultaneous inhibition of multiple muscle-growth inhibitors (myostatin, activin A, GDF-11)
What are the benefits of ACE-031?▾
Dramatic lean mass increases — 2.5 kg in 4 weeks in Phase 2 DMD trial
What are the side effects of ACE-031?▾
Epistaxis (nosebleeds) — most common side effect in trials
What is the recommended dosage for ACE-031?▾
Phase 2 DMD: 1-3mg/kg single SC dose produced 2.5 kg lean mass increase in 4 weeks. Development halted due to vascular side effects (epistaxis, telangiectasias). Research use only with caution.
How long should a ACE-031 cycle last?▾
Monthly cycles or as directed
More Body Composition Peptides
View all Body Composition peptides →MK-677 (Ibutamoren)
Ibutamoren
A non-peptide, orally active growth hormone secretagogue that mimics ghrelin, significantly elevating GH and IGF-1 levels. Unique in being orally bioavailable.
CJC-1295 No DAC (Mod GRF 1-29)
Modified GRF 1-29
A synthetic 29-amino acid GHRH analog with 4 amino acid substitutions that improve stability and receptor affinity compared to Sermorelin. Unlike CJC-1295 DAC, it has no Drug Affinity Complex, giving it a short 30-minute half-life that mimics the body's natural pulsatile GHRH secretion when co-administered with a GHRP.
Follistatin-344
FST-344
A naturally occurring protein that inhibits myostatin and activin, effectively removing the biological ceiling on muscle growth.
MGF (Mechano Growth Factor)
Mechano Growth Factor
A splice variant of IGF-1 released in muscle fibers in response to mechanical damage. Activates muscle satellite cells to initiate repair and hypertrophy.